Progyny (NASDAQ:PGNY) Releases Q3 2026 Earnings Guidance

Progyny (NASDAQ:PGNY) issued an update on its third quarter 2026 earnings guidance on Thursday. The company provided earnings per share guidance of 0.500-0.520 for the period, compared to the consensus estimate of 0.470. The company issued revenue guidance of $335.0 million-$345.0 million, compared to the consensus revenue estimate of $350.2 million. Progyny also updated its FY 2026 guidance to 2.040-2.100 EPS.

Analysts Set New Price Targets

PGNY has been the subject of a number of recent research reports. Truist Financial upped their price objective on shares of Progyny from $30.00 to $33.00 and gave the stock a “buy” rating in a report on Monday, June 22nd. Leerink Partners set a $38.00 target price on Progyny in a report on Wednesday, July 22nd. Canaccord Genuity Group boosted their price target on Progyny from $30.00 to $36.00 and gave the stock a “buy” rating in a research report on Tuesday, July 21st. Citigroup reiterated an “outperform” rating on shares of Progyny in a research note on Monday, May 11th. Finally, Zacks Research raised Progyny from a “hold” rating to a “strong-buy” rating in a report on Wednesday, July 8th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $33.25.

Progyny Trading Down 3.7%

Shares of Progyny stock opened at $30.21 on Friday. Progyny has a 1 year low of $16.10 and a 1 year high of $33.06. The company’s fifty day simple moving average is $29.02 and its 200-day simple moving average is $23.40. The company has a market cap of $2.37 billion, a price-to-earnings ratio of 39.23, a PEG ratio of 2.49 and a beta of 1.01.

Progyny (NASDAQ:PGNY) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.33 by $0.22. Progyny had a net margin of 5.23% and a return on equity of 13.34%. The company had revenue of $350.51 million for the quarter, compared to analyst estimates of $348.63 million. During the same period last year, the business posted $0.19 EPS. The business’s quarterly revenue was up 5.3% on a year-over-year basis. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. As a group, research analysts forecast that Progyny will post 1.19 earnings per share for the current fiscal year.

Progyny announced that its board has authorized a share repurchase program on Tuesday, May 26th that permits the company to buyback $200.00 million in outstanding shares. This buyback authorization permits the company to repurchase up to 10.3% of its shares through open market purchases. Shares buyback programs are typically an indication that the company’s leadership believes its shares are undervalued.

Insider Activity

In other Progyny news, COO Melissa B. Cummings sold 9,578 shares of the firm’s stock in a transaction that occurred on Tuesday, May 19th. The stock was sold at an average price of $25.00, for a total value of $239,450.00. Following the completion of the sale, the chief operating officer owned 73,371 shares in the company, valued at approximately $1,834,275. This trade represents a 11.55% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Mark S. Livingston sold 8,275 shares of Progyny stock in a transaction that occurred on Wednesday, May 20th. The stock was sold at an average price of $25.50, for a total value of $211,012.50. Following the sale, the chief financial officer directly owned 79,063 shares in the company, valued at $2,016,106.50. The trade was a 9.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 36,916 shares of company stock valued at $939,875. Corporate insiders own 9.90% of the company’s stock.

More Progyny News

Here are the key news stories impacting Progyny this week:

• Positive Sentiment: Progyny reported second-quarter adjusted earnings of $0.55 per share, above consensus estimates, while revenue reached $350.5 million, slightly exceeding expectations. EPS increased from $0.19 in the year-ago quarter, and revenue grew 5.3% year over year. Progyny, Inc. Announces Second Quarter 2026 Results
• Positive Sentiment: Management raised or reaffirmed an optimistic full-year profit outlook, guiding 2026 EPS to $2.04-$2.10 versus analyst expectations of $1.86. Full-year revenue guidance of approximately $1.4 billion was broadly in line with consensus. Progyny 2026 Q2 Results Earnings Call Presentation
• Neutral Sentiment: The earnings call and presentation provided additional detail on the quarterly performance and outlook, but the available reports do not indicate a material change to the company’s broader strategy. Progyny Q2 2026 Earnings Call Transcript
• Negative Sentiment: Third-quarter revenue guidance of $335 million-$345 million was below the roughly $350 million analyst consensus. Although the company’s Q3 EPS outlook of $0.50-$0.52 exceeded expectations, investors appear more concerned about the slower near-term top-line outlook, contributing to the negative reaction. Progyny Q2 Earnings and Revenues Beat Estimates

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in PGNY. Wellington Management Group LLP increased its position in Progyny by 260.9% in the 4th quarter. Wellington Management Group LLP now owns 2,243,268 shares of the company’s stock valued at $57,607,000 after acquiring an additional 1,621,688 shares in the last quarter. Loomis Sayles & Co. L P bought a new position in Progyny in the 4th quarter worth approximately $19,917,000. Ameriprise Financial Inc. lifted its holdings in Progyny by 37.6% during the 2nd quarter. Ameriprise Financial Inc. now owns 1,996,957 shares of the company’s stock worth $43,933,000 after buying an additional 545,431 shares in the last quarter. Norges Bank acquired a new position in Progyny during the 4th quarter worth $10,167,000. Finally, Qube Research & Technologies Ltd boosted its position in Progyny by 161.6% in the 3rd quarter. Qube Research & Technologies Ltd now owns 457,015 shares of the company’s stock valued at $9,835,000 after buying an additional 282,322 shares during the last quarter. Institutional investors and hedge funds own 94.93% of the company’s stock.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.